PL369511A1 - Czwartorzędowe sole amoniowe omega-aminoalkiloamidów kwasów R-2-arylo-propionowych i zawierające jekompozycje farmaceutyczne - Google Patents

Czwartorzędowe sole amoniowe omega-aminoalkiloamidów kwasów R-2-arylo-propionowych i zawierające jekompozycje farmaceutyczne

Info

Publication number
PL369511A1
PL369511A1 PL02369511A PL36951102A PL369511A1 PL 369511 A1 PL369511 A1 PL 369511A1 PL 02369511 A PL02369511 A PL 02369511A PL 36951102 A PL36951102 A PL 36951102A PL 369511 A1 PL369511 A1 PL 369511A1
Authority
PL
Poland
Prior art keywords
aminoalkylamides
omega
aryl
pharmaceutical compositions
quaternary ammonium
Prior art date
Application number
PL02369511A
Other languages
English (en)
Other versions
PL214275B1 (pl
Inventor
Marcello Allegretti
Riccardo Bertini
Cinzia Bizzarri
Maria Candida Cesta
Original Assignee
Dompe S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe S.P.A. filed Critical Dompe S.P.A.
Publication of PL369511A1 publication Critical patent/PL369511A1/pl
Publication of PL214275B1 publication Critical patent/PL214275B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/40Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/44Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/01Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/76Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C235/78Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
PL369511A 2001-09-28 2002-09-25 Czwartorzedowe sole amoniowe omega-aminoalkiloamidów kwasów R-2-arylo-propionowych, zawierajace je kompozycje farmaceutyczne i sposób ich wytwarzania PL214275B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2001MI002025A ITMI20012025A1 (it) 2001-09-28 2001-09-28 Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono

Publications (2)

Publication Number Publication Date
PL369511A1 true PL369511A1 (pl) 2005-04-18
PL214275B1 PL214275B1 (pl) 2013-07-31

Family

ID=11448449

Family Applications (1)

Application Number Title Priority Date Filing Date
PL369511A PL214275B1 (pl) 2001-09-28 2002-09-25 Czwartorzedowe sole amoniowe omega-aminoalkiloamidów kwasów R-2-arylo-propionowych, zawierajace je kompozycje farmaceutyczne i sposób ich wytwarzania

Country Status (16)

Country Link
US (1) US7026510B2 (pl)
EP (1) EP1430020B1 (pl)
JP (1) JP4405801B2 (pl)
AU (1) AU2002338784B2 (pl)
CA (1) CA2458035C (pl)
CY (1) CY1117657T1 (pl)
DK (1) DK1430020T3 (pl)
ES (1) ES2573531T3 (pl)
HU (1) HU230541B1 (pl)
IT (1) ITMI20012025A1 (pl)
NO (1) NO328879B1 (pl)
PL (1) PL214275B1 (pl)
PT (1) PT1430020E (pl)
RU (1) RU2291857C2 (pl)
SI (1) SI1430020T1 (pl)
WO (1) WO2003029187A1 (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457485A1 (en) * 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonic acids, their derivatives and pharmaceutical compositions containing them
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
PL1776336T3 (pl) * 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
CA2589495C (en) * 2004-12-15 2013-10-01 Dompe Pha.R.Ma. S.P.A. 2-arylpropionic acid derivatives and pharmaceutical compositions containing them
EP1739078A1 (de) 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
WO2008012605A1 (en) * 2006-07-27 2008-01-31 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of ketoprofen and related compounds with very fast skin penetration rate
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
WO2008010025A1 (en) * 2006-07-18 2008-01-24 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
CN104610077B (zh) * 2006-07-27 2020-04-14 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性酮洛芬及相关化合物的前药
ES2559781T3 (es) * 2006-08-08 2016-02-15 Techfields Biochem Co. Ltd Profármacos de ácidos aril- y heteroarilacéticos solubles en agua y con carga positiva con una tasa de penetración en piel muy rápida
CN103772259B (zh) * 2006-08-08 2016-08-31 于崇曦 具有快速皮肤穿透速度的带正电荷的芳基和杂芳基乙酸类前药
CN103772258B (zh) * 2006-08-08 2016-09-28 于崇曦 具有快速皮肤穿透速度的带正电荷的芳基和杂芳基乙酸类前药
AU2013206218B2 (en) * 2006-08-15 2016-06-30 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
JP5424880B2 (ja) * 2006-08-15 2014-02-26 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
KR20150058566A (ko) 2007-06-04 2015-05-28 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 nsaia 약물전구체 및 이들의 새로운 의약적 용도
RU2475486C2 (ru) * 2007-10-18 2013-02-20 Домпе С.П.А. (r)-4-(гетероарил)фенилэтильные производные и содержащие их фармацевтические композиции
BR122021011394B1 (pt) 2008-12-04 2021-09-28 Chongxi Yu Composição de alta penetração de um fármaco principal, e uso de uma hpc
RS54998B1 (sr) 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
JP6205133B2 (ja) 2009-07-10 2017-09-27 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー
KR20130073822A (ko) 2011-12-23 2013-07-03 가부시키가이샤 한도오따이 에네루기 켄큐쇼 이온 액체, 비수 전해질 및 축전 장치
JP5940036B2 (ja) * 2013-10-08 2016-06-29 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
BR112016028081A2 (pt) * 2014-05-30 2017-08-22 Sphaera Pharma Private Ltd Novos compostos como agentes antituberculares
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
KR20180069782A (ko) * 2015-08-03 2018-06-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 하전 이온 채널 블록커 및 이용 방법
JP7339733B2 (ja) 2016-01-14 2023-09-06 ケモセントリックス,インコーポレイティド C3腎症を処置する方法
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
US10562896B2 (en) 2017-05-31 2020-02-18 Chemocentryx, Inc. 6-5 fused rings as C5a inhibitors
WO2018222601A1 (en) 2017-05-31 2018-12-06 Chemocentryx, Inc. 5-5 FUSED RINGS AS C5a INHIBITORS
CA3077395A1 (en) 2017-10-30 2019-05-09 Chemocentryx, Inc. Deuterated compounds as immunomodulators
MX2020006460A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillo 5,5 fusionado sustituido con diarilo como inhibidores de c5ar.
WO2019126424A1 (en) 2017-12-22 2019-06-27 Chemocentryx, Inc. DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
BR112020019822A2 (pt) 2018-04-02 2021-03-16 Chemocentryx, Inc. Profármacos de antagonistas bicíclicos fundidos de c5ar
WO2020142657A1 (en) * 2019-01-03 2020-07-09 President And Fellows Of Harvard College Charged ion channel blockers and methods for use thereof
AU2020235888A1 (en) 2019-03-11 2021-09-30 Nocion Therapeutics, Inc. Charged ION channel blockers and methods for use
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
MX2021010869A (es) 2019-03-11 2022-01-19 Nocion Therapeutics Inc Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso.
US10934263B2 (en) 2019-03-11 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN114828845A (zh) 2019-11-06 2022-07-29 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US12162851B2 (en) 2020-03-11 2024-12-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN119118953A (zh) 2020-03-11 2024-12-13 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593024A (pl) * 1968-09-18 1970-05-25
IT1090782B (it) 1977-11-30 1985-06-26 Menarini Sas 2 4 bifenilil 2 dietilamino alchil propionamide suoi sali e procedimenti di fabbricazione relativi
RU2105554C1 (ru) * 1997-06-24 1998-02-27 Всероссийский научный центр по безопасности биологически активных веществ N-(2,4,6-триметилфенилкарбамоилметил)-n-аллилморфолиний бромид, проявляющий противоишемическое и антиаритмическое действие при ишемической болезни сердца и способ его получения
IT1317826B1 (it) 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
ITMI20010395A1 (it) * 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate

Also Published As

Publication number Publication date
HUP0401763A2 (hu) 2004-12-28
US20040266870A1 (en) 2004-12-30
RU2291857C2 (ru) 2007-01-20
JP4405801B2 (ja) 2010-01-27
CA2458035C (en) 2011-04-12
AU2002338784B2 (en) 2008-08-14
NO328879B1 (no) 2010-06-07
NO20041609L (no) 2004-04-20
ITMI20012025A1 (it) 2003-03-28
DK1430020T3 (en) 2016-05-30
CA2458035A1 (en) 2003-04-10
PT1430020E (pt) 2016-06-08
EP1430020B1 (en) 2016-03-02
RU2004113099A (ru) 2005-09-10
WO2003029187A1 (en) 2003-04-10
HUP0401763A3 (en) 2006-01-30
EP1430020A1 (en) 2004-06-23
PL214275B1 (pl) 2013-07-31
US7026510B2 (en) 2006-04-11
ES2573531T3 (es) 2016-06-08
CY1117657T1 (el) 2017-05-17
ITMI20012025A0 (it) 2001-09-28
JP2005504121A (ja) 2005-02-10
HU230541B1 (hu) 2016-11-28
SI1430020T1 (sl) 2016-06-30

Similar Documents

Publication Publication Date Title
PL369511A1 (pl) Czwartorzędowe sole amoniowe omega-aminoalkiloamidów kwasów R-2-arylo-propionowych i zawierające jekompozycje farmaceutyczne
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
IL209444A0 (en) O-desmethyl-venlafaxine succinate salts and pharmaceutical compositions containing them
HUP0303810A3 (en) Carboxylic acid derivative and salt thereof and pharmaceutical compositions containing them
HUP0302656A3 (en) Fumaric acid amides, their use for preparation of pharmaceutical compositions and pharmaceutical compositions containing the compounds
HUP0201334A3 (en) Hydrochloride of fused-heterocycle compound and pharmaceutical compositions containing the same
IL155196A0 (en) Benzamide derivatives and pharmaceutical compositions containing the same
HUP0400052A3 (en) Carboxamide-substituted phenylurea derivatives and pharmaceutical compositions containing them and their use
HUP0501089A2 (en) Therapeutic isoquinoline compounds and pharmaceutical compositions coutaining them
HUP0401950A3 (en) Pyrimidine derivatives and pharmaceutical compositions containing that compounds
HUP0400974A3 (en) Peptide-based compounds and pharmaceutical compositions containing them
HUP0401333A3 (en) Spiropyrazole compounds and pharmaceutical compositions containing them
HUP0001471A3 (en) Pharmaceutical compositions containing amoxicilline and clavulanic acid potassium salt
HUP0500017A3 (en) Alkyl ether derivatives or salts thereof and pharmaceutical compositions containing them
EP1420767A4 (en) COMPOSITIONS WITH ITRACONAZOLE AND THEIR PRODUCTION PROCESS
HUP0303998A3 (en) Phthalazinones derivatives and pharmaceutical compositions containing them
HUP0105204A3 (en) Substituted phenethylamine derivatives and pharmaceutical compositions containing them
HUP0400801A3 (en) Pharmaceutical compositions containing bile acid or bile salt fatty acid conjugates and their use
SI2157083T1 (sl) Farmacevtske sestave, vsebujoče kristalno obliko (i) lerkanidipin hidroklorida
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
EP1458681A4 (en) HYDROPHILIC SALTS OF (S) -AMLODIPINE OR THEIR HYDRATES AND PHARMACEUTICAL COMPOSITIONS
HUP0300402A3 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain and pharmaceutical compositions containing them
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
HUP0401572A3 (en) Alpha-ketoglutarates of l-carnitine and compositions containing same
HUP0401862A3 (en) Novel heterocyclic compound and medicinal use thereof and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
RECP Rectifications of patent specification